Journal Mobile Options
Table of Contents
Vol. 6, No. 1, 2003
Issue release date: April 2003
Community Genet 2003;6:29–36

Attitudes towards Genetic Screening for Predisposition to Colon Cancer among Cancer Patients, Their Relatives and Members of the Community

Results of Focus Group Interviews

Ramsey S.D. · Wilson S. · Spencer A. · Geidzinska A. · Newcomb P.
aFred Hutchinson Cancer Research Center, bDepartment of Medicine, University of Washington, Seattle, Wash., cUniversity of Southern California, Los Angeles, Calif., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objective: To compare knowledge of and interest in genetic testing for hereditary colon cancer syndromes. Methods: Colorectal cancer patients, first-degree relatives of colon cancer patients and controls were recruited from a familial cancer registry. Focus groups explored attitudes about genetic testing. Results: All three groups conveyed interest in testing, but lacked knowledge about testing and its implications. After receiving information regarding the potential benefits and costs of testing (including insurance and employment issues) all three groups were disinclined to be tested. The reasons varied among risk groups. Conclusions: When informed about the costs and implications of testing, individuals may be reluctant to undergo genetic testing, regardless of baseline risk. Barriers to testing will vary depending on the perceived risk of carrying a mutation

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. American Cancer Society Cancer Facts & Figures 2001. Atlanta, American Cancer Society, 2001.
  2. Potter JD: Colorectal cancer: Molecules and populations. J Natl Cancer Inst 1999;91:916–932.
  3. Lerman C, Narod S, Schulman K, Hughes C, Gomez-Caminero A, Bonney G, Gold K, Trock B, Main D, Lynch J, Fulmore C, Snyder C, Lemon SJ, Conway T, Tonin P, Lenoir G, Lynch H: BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA 1996;275:1885–1892.
  4. Lerman C, Hughes C, Trock BJ, Myers RE, Main D, Bonney A, Abbaszadegan MR, Harty AE, Franklin BA, Lynch JF, Lynch HT: Genetic testing in families with hereditary nonpolyposis colon cancer. JAMA 1999;281:1618–1622.
  5. Järvinen HJ, Mecklin JP, Sistonen P: Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 1995;108:1405–1411.
  6. Järvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomaki P, De La Chapelle A, Mecklin JP: Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000;118:829–834.
  7. Lynch HT, Watson P, Shaw TG, Lynch JF, Harty AE, Franklin BA, Kapler CR, Tinley ST, Liu B, Lerman C: Clinical impact of molecular genetic diagnosis, genetic counseling, and management of hereditary cancer. 2. Hereditary nonpolyposis colorectal carcinoma as a model. Cancer 1999;86:2457–2463.
  8. Croyle RT, Lerman C: Interest in genetic testing for colon cancer susceptibility: Cognitive and emotional correlates. Prev Med 1993;22:284–292
  9. Kinney AY, DeVellis BM, Skrzynia C, Millikan R: Genetic testing for colorectal carcinoma susceptibility. Cancer 2001;91:57–65.
  10. Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, Khan PM, Lynch H, Perucho M, Smyrk T, Sobin L, Srivastava S: A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: Meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997;89:1758–1762.
  11. Nakahara M, Yokozaki H, Yasui W, Dohi K, Tahara E: Identification of concurrent germ-line mutations in hMSH2 and/or hMLH1 in Japanese hereditary nonpolyposis colorectal cancer kindreds. Cancer Epidemiol Biomark Prev 1997;6:1057–1064.
  12. Vasen HF, Mecklin JP, Khan PM, Lynch HT: The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991;34:424–425.
  13. Krueger RA: Focus Groups: A Practical Guide for Applied Research, ed 2. Thousand Oaks, Sage Publications, 1994, p 4.
  14. Steward DW, Shamdasani PN: Focus Groups: Theory and Practice. Newbury Park, Sage Publications, 1990, p 15.
  15. National Cancer Institute: Colon Cancer Family Registries Objectives.
  16. Krippendorf, K: Content analysis: An introduction to its methodology. Beverly Hills, Sage Publications, 1980, p 21.
  18. Lerman C, Marshall J, Audrain J, Gomez-Caminero A: Genetic testing for colon cancer susceptibility: Anticipated reactions of patients and challenges to providers. Int J Cancer 1996;69:58–61.
  19. Codori AM, Petersen GM, Miglioretti DL, Larkin EK, Bushey MT, Young C, Brensinger JD, Johnson K, Bacon JA, Booker SV: Attitudes toward colon cancer gene testing: Factors predicting test uptake. Cancer Epidemiol Biomark Prev 1999;8:345–351.
  20. Vernon SW, Gritz ER, Peterson SK, Perz CA, Marani S, Amos CI, Baile WF: Intention to learn results of genetic testing for hereditary colon cancer. Cancer Epidemiol Biomark Prev 1999;8:353–360.
  21. Petersen GM, Larkin E, Codori AM, Wang CY, Booker SV, Bacon J, Giardiello FM, Boyd PA: Attitudes toward colon cancer gene testing: Survey of relatives of colon cancer patients. Cancer Epidemiol Biomark Prev 1999;8:337–344.
  22. Glanz K, Grove J, Lerman C, Gotay C, Le Marchand L: Correlates of intentions to obtain genetic counseling and colorectal cancer gene testing among at-risk relatives from three ethnic groups. Cancer Epidemiol Biomark Prev 1999;8:329–336.
  23. Smith KR, Croyle RT: Attitudes toward genetic testing for colon cancer risk. Am J Public Health 1995;85:1435–1438.
  24. Todora HM, Skinner CS, Gidday L, Ivanovich JL, Rawl S, Whelan AJ: Perceptions of genetic risk assessment and education among first-degree relatives of colorectal cancer patients and implications for physicians. Fam Pract 2001;18:367–372.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50